This resource is intended to serve as a guide on available outpatient COVID-19 treatment options, with links to FDA prescribing information, IDSA guidelines, and national guideline-developing organizations. It is not intended to provide medical advice or professional guidance to individual patients. Finally, the guidelines referenced here may not consider local allocation and availability of scarce resources. Additional information or resources to access these therapies can be found at the National Infusion Center Association, and other national organizations.

The roadmap is not intended to represent a prioritization scheme for therapeutic choices. For information on prioritization of one outpatient treatment over another, see IDSA guidelines on the therapeutic management of non-hospitalized adults with COVID-19 and ASPR Clinical Decision Aid.

### References
1. National Infusion Center Association Website.
3. IDSA’s guidelines on the treatment and management of patients with COVID-19 (December 2021).
drug-information
7. IDSA guidelines on the treatment and management of patients with COVID-19 (June 2021). Available at: https://www.idsa.org/guidelines/covid-19/
8. REMdesivir (Veklury) Package Insert (Prescribing Information) with the extended approval for outpatient use (March 2021).
14. COVID-19, including its consequences. Available at: https://www.cdc.gov/coronavirus/2019-ncov/about/conditions.html
15. Pandemic influenza A (H1N1) 2009. Available at: https://www.cdc.gov/flu/p Riyadh/2009h1n/2009h1n1.htm
16. ricin. Available at: https://www.cdc.gov/pandemicflu/2009h1n1.html
19. COVID-19 Vaccine Guide for People with HIV. Available at: https://www.cdc.gov/hiv/diagnose/2021/vaccines.html